ArticleNature communications2019
NADP
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 61 citations in OpenAlex.
- Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma.Cancer letters · 2026Article
- Mitochondrial NADP(H)-dependent de novo dTMP biosynthesis counteracts the cytotoxicity of PARP inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.Medical oncology (Northwood, London, England) · 2026Review
- The aberration of key amino acids participated one-carbon metabolism may jeopardize genetic stability in cancer development.Cell communication and signaling : CCS · 2026Review
- Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADPInternational journal of biological sciences · 2026Article
- Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies.Journal of Zhejiang University. Science. B · 2025Review
- Effects of aging and anti-aging dietary restriction on regulators of the [NADPH]/[NADPFree radical biology & medicine · 2025Review
- Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications.Journal of ovarian research · 2025Review
- Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.Science advances · 2025Article
- NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro.International journal of molecular sciences · 2025Article
- Adenosine diphosphate-ribosylation greatly affects proteins function: a focus on neurodegenerative diseases.Frontiers in aging neuroscience · 2025Review
- Impact of NAD+ metabolism on ovarian aging.Immunity & ageing : I & A · 2023Review
- Hyperpolarized Carbon-13 MRI in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- LncFALEC recruits ART5/PARP1 and promotes castration-resistant prostate cancer through enhancing PARP1-meditated self PARylation.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.Cell reports · 2023Article
- Advances in PARP Inhibitors for Prostate Cancer.Cancers · 2023Review
- Nicotinamide adenine dinucleotide kinase promotes lymph node metastasis of NSCLC via activating ID1 expression through BMP pathway.International journal of biological sciences · 2023Article
- Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).Oncology reports · 2022Article
- AMPK phosphorylates NAMPT to regulate NADOpen biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Chunjing BianDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Chao ZhangDepartment of General Surgery of Xuanwu Hospital, Capital Medical University, 100053, Beijing, China.
Tao LuoVascular Surgery Department of Xuanwu Hospital, Institute of Vascular Surgery, Capital Medical University, 100053, Beijing, China.
Aditi VyasDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.ORCID http://orcid.org/0000-0003-4763-0600
Shih-Hsun ChenDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Chao LiuDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Muzaffer Ahmad KassabDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Ying YangDepartment of Cancer Biology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Mei KongDepartment of Cancer Biology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.ORCID http://orcid.org/0000-0001-8139-2349
Xiaochun YuDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA. xyu@coh.org.
City of Hope · USCity Of Hope National Medical Center · USCapital Medical University · CN
Funding
Regulation of Ionizing Radiation-Induced DNA Damage ResponseR01CA130899 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIU, YILUN · 2009 to 2023
$5.5MMolecular Mechanisms of BRCA1-Dependent DNA Damage Response and TumorogenesisR01CA132755 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHEN, BINGHUI · 2008 to 2019
$3.5MFunctional analysis of BRCA1 in DNA damage response and tumor suppressionR01CA187209 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YU, XIAOCHUN · 2014 to 2018
$1.7MNCI NIH HHS R01 CA130899NCI NIH HHS R01 CA132755NCI NIH HHS R01 CA187209
Abstract
ADP-ribosylation is a unique posttranslational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) using NAD
Indexed as
ADP-RibosylationAnimalsAntineoplastic AgentsBiomarkersCell Line, TumorDNA DamageDNA RepairFanconi Anemia Complementation Group ProteinsFemaleHumansMiceNADNADPOvarian NeoplasmsPhosphotransferases (Alcohol Group Acceptor)Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsBiomarkersBRIP1 protein, humanFanconi Anemia Complementation Group ProteinsNADNAD kinaseNADPPhosphotransferases (Alcohol Group Acceptor)Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRNA Helicases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.